Literature DB >> 7527749

Integral membrane proteins associated with the nuclear lamina are novel autoimmune antigens of the nuclear envelope.

K Konstantinov1, R Foisner, D Byrd, F T Liu, W M Tsai, A Wiik, L Gerace.   

Abstract

We have analyzed sera from 55 patients, most with rheumatic diseases, that all react with the nuclear envelope of human cells in immunofluorescence microscopy. The molecular targets of these autoantibodies were characterized by immunoblot analysis of fractions derived from rat liver nuclear envelopes. While numerous sera were found to react with previously characterized autoimmune antigens of the nuclear envelope including nuclear lamins and the pore complex glycoprotein gp210, a substantial number of the sera were found to recognize relatively minor integral membrane proteins of the nuclear envelope associated with the nuclear lamina (LAP 1A and LAP 2), which have not been previously identified as autoantigens. Autoantibodies to LAP 1A and LAP 2 are present in 9 and 29% of the patient sera, respectively. Only autoantibodies to lamins A/C were encountered more frequently (in 31% of the sera) than autoantibodies to LAP 2, suggesting that LAP 2 may be among one of the most prominent autoantigens of the nuclear envelope in rheumatic disease patients. Since recent studies have suggested that LAP 1A and LAP 2 may be involved in attaching lamins and chromosomes to the nuclear envelope, these findings could promoted understanding of nuclear envelope functions as well as autoimmunity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7527749     DOI: 10.1006/clin.1995.1013

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  8 in total

1.  Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome.

Authors:  K Konstantinov; A von Mikecz; D Buchwald; J Jones; L Gerace; E M Tan
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

2.  Primary biliary cirrhosis sera recognize not only gp210 but also proteins of the p62 complex bearing N-acetylglucosamine residues from rat liver nuclear envelope. Anti-p62 complex antibody in PBC.

Authors:  K Miyachi; M Shibata; Y Onozuka; F Kikuchi; N Imai; T Horigome
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

3.  The nuclear pore complex protein Tpr is a common autoantigen in sera that demonstrate nuclear envelope staining by indirect immunofluorescence.

Authors:  Y Ou; P Enarson; J B Rattner; S G Barr; M J Fritzler
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

Review 4.  Autoantigens of the nuclear pore complex.

Authors:  P Enarson; J B Rattner; Y Ou; K Miyachi; T Horigome; M J Fritzler
Journal:  J Mol Med (Berl)       Date:  2004-06-03       Impact factor: 4.599

5.  An autoimmune myositis-overlap syndrome associated with autoantibodies to nuclear pore complexes: description and long-term follow-up of the anti-Nup syndrome.

Authors:  Jean-Luc Senécal; Catherine Isabelle; Marvin J Fritzler; Ira N Targoff; Rose Goldstein; Michel Gagné; Jean-Pierre Raynauld; France Joyal; Yves Troyanov; Marie-Christine Dabauvalle
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

6.  Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective.

Authors:  Jan Damoiseaux; Luis Eduardo Coelho Andrade; Orlando Gabriel Carballo; Karsten Conrad; Paulo Luiz Carvalho Francescantonio; Marvin J Fritzler; Ignacio Garcia de la Torre; Manfred Herold; Werner Klotz; Wilson de Melo Cruvinel; Tsuneyo Mimori; Carlos von Muhlen; Minoru Satoh; Edward K Chan
Journal:  Ann Rheum Dis       Date:  2019-03-12       Impact factor: 19.103

Review 7.  Molecular basis of a pandemic of avian-type influenza virus.

Authors:  Nongluk Sriwilaijaroen; Yasuo Suzuki
Journal:  Methods Mol Biol       Date:  2014

8.  Cloning of a cDNA for lamina-associated polypeptide 2 (LAP2) and identification of regions that specify targeting to the nuclear envelope.

Authors:  K Furukawa; N Panté; U Aebi; L Gerace
Journal:  EMBO J       Date:  1995-04-18       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.